Physician profile
Narinder Kumar Batra
NPI 1730281361
$7,725.49
in general payments reported to CMS, 2019-2025
32 companies · $1,257 in 2025
The $1,257 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $986 · 2020: $611 · 2021: $1,603 · 2022: $798 · 2023: $1,264 · 2024: $1,207 · 2025: $1,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,728.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,933.12 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $867.63 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $822.28 | 2019-2025 | Wegovy |
| Pfizer INC. | $710.33 | 2019-2025 | |
| Glaxosmithkline, LLC. | $527.70 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $391.80 | 2023-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $335.34 | 2021 | |
| Amarin Pharma, INC. | $272.16 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $234.24 | 2019-2022 | |
| Lundbeck LLC | $207.91 | 2023-2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $195.93 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $155.69 | 2019-2023 | Eliquis |
| Allergan, INC. | $146.19 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.13 | 2021-2022 | |
| Exact Sciences Corporation | $113.52 | 2023-2024 | Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $108.02 | 2021-2023 | Vraylar |
| Dexcom, INC. | $99.78 | 2021-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $88.85 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $77.01 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $55.98 | 2021 | |
| Sunovion Pharmaceuticals INC. | $47.15 | 2019 | |
| Amgen INC. | $28.54 | 2019-2025 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.06 | 2019 | |
| Alkermes, INC. | $24.90 | 2021 | |
| Sanofi Pasteur INC. | $24.71 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $21.08 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $18.75 | 2022 | |
| Corcept Therapeutics | $16.93 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.99 | 2020 | |
| Indivior INC. | $14.80 | 2023 | Sublocade |
| Novartis Pharmaceuticals Corporation | $12.55 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narinder Batra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.